← All trials
NCT03413800
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 12, 2018
- Primary completion
- Jan 29, 2021
- Completion date
- Jan 29, 2023
- First posted
- —
- Last posted
- —
- Enrollment
- 15
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ciusss de L'Est de l'Île de MontréalLead sponsor
- CelgeneCollaborator
- Ciusss de L'Est de l'Île de MontréalReponsible party - principal investigator
- Ciusss de L'Est de l'Île de MontréalOverall official - principal investigator
- Centre de Commercialisation en Immunothérapie du CancerCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.